- Conditions
- Cerebral Palsy, Stroke, Premature Birth, Hypoxic-Ischemic Encephalopathy, Periventricular Leukomalacia
- Interventions
- Mobility Device, Spinal Stimulation
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 4 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 6,923
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Ovarian Cancer
- Interventions
- AST-201, Paclitaxel, Carboplatin, Placebo, rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
- Biological · Drug
- Lead sponsor
- Aston Sci. Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Seizure Disorder
- Interventions
- External Trigeminal Nerve Stimulation (eTNS)
- Device
- Lead sponsor
- NeuroSigma, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Sylmar, California
- Conditions
- Type B Aortic Dissection
- Interventions
- Auricular Vagus Nerve Stimulator, 3D Printed Earpiece
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Parkinson Disease
- Interventions
- Vibrotactile coordinated reset
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Deafness, Bilateral
- Interventions
- Parent-Child Early Approaches to Raising Language Skills, Standard Care Speech therapy
- Behavioral · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 12 Months to 48 Months
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Spinal Cord Injury
- Interventions
- rhythmic auditory stimulation
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Spinal Cord Injury Cervical
- Interventions
- Active Stimulation, Sham, Training only
- Other
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Parkinson's Disease
- Interventions
- Novel DBS stimulation patterns
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Anaemia
- Interventions
- GSK1278863, rhEPO
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Azusa, California • La Mesa, California + 21 more
- Conditions
- Brain Concussion, Brain Trauma, Attention Concentration Difficulty, Brain Injuries, Brain Injuries, Traumatic, Neurocognitive Dysfunction, Attention Impaired, Memory Impairment, Mild Traumatic Brain Injury, Mild Cognitive Impairment
- Interventions
- active tDCS and cognitive training intervention, sham tDCS and cognitive training intervention
- Combination Product
- Lead sponsor
- United States Naval Medical Center, San Diego
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 3
- Interventions
- UG3NS140720 Deep Brain Stimulation System
- Device
- Lead sponsor
- Gordon H. Baltuch
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Granulocyte Colony Stimulating Factor (GCSF)
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Healthy
- Interventions
- Magstim Rapid Magnetic Stimulator
- Device
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- cTBS, iTBS, sham
- Device
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Spasmodic Dysphonia, Laryngeal Dystonia
- Interventions
- 1Hz repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Opioid Use Disorder
- Interventions
- Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Stroke, Stroke, Chronic, Stroke, Middle Cerebral Artery With Infarction
- Interventions
- Active continuous theta burst stimulation (cTBS), Placebo (Sham) continuous theta burst stimulation, Motor Practice
- Device · Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Muscle Weakness
- Interventions
- The ZELTIQ System
- Device
- Lead sponsor
- Zeltiq Aesthetics
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Pleasanton, California